nafamostat has been researched along with B Virus Infection in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J | 1 |
| Dai, L | 1 |
| Barrett, L | 1 |
| James, J | 1 |
| Plaisance-Bonstaff, K | 1 |
| Post, SR | 1 |
| Qin, Z | 1 |
1 other study available for nafamostat and B Virus Infection
| Article | Year |
|---|---|
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus.
Topics: Antiviral Agents; Azithromycin; Benzamidines; Cell Line; COVID-19; COVID-19 Drug Treatment; Guanidin | 2021 |